Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids Pharmaceutical Investing
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BELLUS Health Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2021 - BLU Biotech Investing
BLU INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BELLUS Health Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BLU Biotech Investing
BLU LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving BELLUS Health Inc. Biotech Investing
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of BELLUS Health Inc. Investors Biotech Investing
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BELLUS Health Inc. Biotech Investing
Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2 Pharmaceutical Investing
Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts Pharmaceutical Investing
FDA Approves Merck's KEYTRUDA® Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinoma Pharmaceutical Investing
